Rethinking the Mechanistic Landscape of Antimicrobial Therapy

Rethinking the Mechanistic Landscape of Antimicrobial Therapy
Author: David Alvaro, PhD
Published date: 20 October 2026
Category:
Human Health Innovation
Share

The conventional map of antibacterial action is familiar. Established drugs interfere with cell-wall synthesis, protein synthesis, nucleic-acid processes, folate and other metabolic pathways, or membrane integrity and function. These categories remain useful, but they identify broad areas of bacterial vulnerability more clearly than they predict which targets can support future therapies.

A promising target must matter under clinically relevant conditions and support an intervention that can reach it, discriminate sufficiently between pathogen and host, and produce an appropriate spectrum of activity. Developers must also consider how readily bacteria could evade the intervention, whether the compound can achieve useful exposure without unacceptable toxicity, and how the mechanism might function in combination with other treatments.

The remaining antimicrobial landscape therefore includes familiar processes examined with greater resolution, as well as targets outside the categories that have historically dominated treatment. Outer-membrane assembly, lipopolysaccharide transport, conserved non-protein building blocks, bacterial cell division, and virulence functions offer different routes for intervention. Each also reveals why biological vulnerability is only the beginning of target selection.

What Makes a Good Antimicrobial Target?

Essentiality provides an intuitive starting point. If a bacterium cannot survive or reproduce without a particular gene product or pathway, disrupting it would appear to offer a direct route to treatment. Essentiality, however, is not always a fixed property.

A study examining approximately 3,400 nearly ubiquitous genes across 18 representative Escherichia coli strains and three growth conditions found extensive variation in which genes were essential.1 A gene required by one strain under one condition could be dispensable in another genetic or environmental context. Research in Streptococcus pneumoniae similarly found that the bacterial pan-genome can make essentiality strain-dependent and evolvable. Accessory genes, pathway redundancy, metabolite recycling, toxic intermediates, and pathway rewiring all influenced whether particular genes were required.2 Even so, disruption of many differentially essential genes still imposed substantial fitness costs in vivo, suggesting that context-dependent targets should not automatically be discarded.

These findings make essentiality a question that must be defined experimentally. Developers need to know whether the target matters in the relevant organisms, across the strains the therapy is intended to cover, and under conditions that adequately represent the intended use.

Selectivity presents a separate test. Target identity contributes to selectivity, but the compound must still demonstrate an acceptable separation between antibacterial activity and host effects.

Accessibility can be equally decisive. One research group identified two central and independent problems in antibacterial discovery: choosing targets that are not prone to rapid resistance and finding compounds capable of overcoming bacterial entry and efflux barriers, particularly in Gram-negative organisms.3 A compelling intracellular target has limited therapeutic value if a compound cannot reach and remain at it in an effective concentration.

Work on compound accumulation in E. coli illustrates how directly this problem can be investigated. Researchers tested more than 180 structurally diverse compounds and identified molecular properties associated with bacterial accumulation, including the presence of an amine, amphiphilicity, rigidity, and low globularity.4 Applying those findings enabled the conversion of a natural product active only against Gram-positive bacteria into a compound with activity against a panel of multidrug-resistant Gram-negative pathogens. Penetration can therefore be treated as a design parameter rather than deferred until late in development.

Spectrum belongs within the same early assessment. A target-compound combination may support activity across multiple organisms or produce a much narrower profile. The value of either outcome depends on the intended use and the organisms the therapy must cover. Target conservation contributes to spectrum, but it does not determine it by itself.

Resistance liability adds another consideration. Target selection should account for whether bacteria can alter the target, protect it, bypass the inhibited function, or reduce the concentration of the drug that reaches it. Compatibility with combination treatment may also matter when a second intervention could complement the mechanism or make escape more difficult. Combination potential should be evaluated rather than assumed, since no pairing can be expected to prevent resistance automatically.

A viable target must also be connected to a viable drug. Biochemical inhibition does not establish whole-cell activity, acceptable exposure, tolerability, or efficacy in vivo.

The Established Map as a Starting Point

Cell-wall synthesis, ribosomal and protein synthesis, nucleic-acid processes, folate and other metabolic pathways, and membranes remain the principal categories used to organize established antibacterial mechanisms.5 They provide a necessary baseline, but each category is broad enough to contain multiple possible points of intervention.

Their continued relevance does not require treating the antimicrobial landscape as closed. Existing target classes can contain overlooked vulnerabilities, while familiar bacterial structures may be attacked through mechanisms that differ substantially from those used by established drugs. A cell-wall strategy, for example, can be distinguished by whether it acts on a protein target or recognizes conserved molecular precursors.6 Envelope-focused strategies can likewise differ according to whether they affect the membrane directly or interfere with machinery involved in envelope construction.7,8

The established categories are thus most useful as coordinates. They show where antibacterial therapy has already succeeded while providing a reference point for evaluating newer approaches that attack different structures, processes, or pathogenic functions.

New Vulnerabilities in the Gram-Negative Envelope

The Gram-negative envelope creates a barrier to compound accumulation, but the machinery responsible for constructing and maintaining that envelope also presents potential targets.

One example is BamA, an essential component of the machinery that folds and inserts proteins into the outer membrane. Darobactin provided experimental evidence that this machinery can be inhibited. The compound was active against important Gram-negative pathogens in vitro and in animal models, and resistant mutants recovered during the study mapped to BamA. Its reported mechanism involved inhibition of β-barrel assembly machinery activity through binding to BamA.7

Its position within outer-membrane protein assembly suggests that targeting BamA may present a different accessibility problem from targeting machinery deeper inside the bacterial cell. The darobactin findings also show that an essential target in this location can retain mutational routes that reduce susceptibility. Accessibility and resistance barrier must therefore be evaluated separately.

Lipopolysaccharide (LPS) transport offers another way to interfere with Gram-negative envelope construction. Zosurabalpin belongs to a class of tethered macrocyclic peptides that inhibit the LptB₂FGC complex responsible for transporting LPS from the inner membrane toward the outer membrane in Acinetobacter baumannii. The work established LptB₂FGC as a tractable antibacterial target and demonstrated activity against carbapenem-resistant A. baumannii in laboratory and animal experiments.8

The compound’s spectrum was highly focused. It showed activity against A. baumannii but limited activity against the other Gram-negative and Gram-positive organisms included in the reported testing. Its development also illustrates the distance between identifying a target and selecting a viable candidate. The reported optimization process considered antibacterial activity alongside plasma precipitation and tolerability in rats. Resistance studies identified mutations involving lptF and lptG, the LPS-biosynthesis gene lpxM, and the regulatory genes adeR and adeS.8

Zosurabalpin is particularly useful for understanding pathogen-focused activity. The target is essential and chemically tractable, but the resulting compound does not act broadly across bacteria. Its value must instead be considered in relation to the organism it covers, the resistance routes observed, and the properties required to turn target engagement into a viable candidate.

Targeting Conserved Non-Protein Precursors

Many target-discovery programs concentrate on bacterial proteins, but essential non-protein structures provide another possibility. Teixobactin inhibits cell-wall synthesis by binding conserved motifs in lipid II, a peptidoglycan precursor, and lipid III, a wall teichoic acid precursor.6

In a teixobactin study, researchers did not recover resistant Staphylococcus aureus or Mycobacterium tuberculosis mutants under the conditions tested.6 The result supports further investigation of conserved precursor structures as targets with potentially high experimental barriers to resistance but does not establish that resistance can never arise during broader or prolonged use.

The significance of teixobactin lies in the type of target it recognizes. The search for antimicrobial targets with higher resistance barriers need not be limited to finding additional proteins. Conserved molecular building blocks shared across essential biosynthetic products may provide another route for intervention, although the resistance barrier must be established for each target and compound.

Stopping Bacterial Cell Division

Bacterial cell division offers a mechanistic space outside the dominant established drug classes. FtsZ is an essential bacterial guanosine triphosphatase that polymerizes into a structure involved in initiating cell division. PC190723 inhibited FtsZ, prevented cell division, and produced potent, selective bactericidal activity against staphylococci, including resistant S. aureus strains, in the reported study. The compound also showed efficacy in a mouse infection model.9

FtsZ separates essentiality from spectrum. Although the target performs an essential bacterial function, the activity reported for PC190723 was selective for staphylococci. Identifying an indispensable process does not establish how broadly a compound acting on that process will work.

The study nevertheless demonstrates that a target outside the conventional categories can achieve biological and pharmacologic validation. FtsZ inhibition progressed beyond activity against an isolated target to whole-cell effects and efficacy in an animal model, supplying several layers of evidence that target essentiality alone could not provide.

Disarming Bacteria Rather Than Directly Inhibiting Growth

Antivirulence strategies broaden the mechanistic landscape by targeting functions that bacteria use to cause disease rather than functions required for growth. A review of studies published from 2017 through 2021 found that work in this area had focused especially on adhesion, toxins, and bacterial communication, with additional attention to other regulatory and pathogenicity-related systems.10

This approach changes the standard used to judge a target. The relevant endpoint may be suppression of a pathogenic function rather than direct inhibition of bacterial growth. As a result, demonstrating that the mechanism alters infection requires evidence suited to the particular virulence process and intended therapeutic effect.

In that review, relatively few antivirulence candidates had been tested in vivo, and the authors identified incomplete pathogen clearance as a potential problem, particularly for immunocompromised patients. They also discussed combining antivirulence agents with conventional antibiotics as one possible strategy.

Antivirulence therapy therefore represents a distinct therapeutic logic rather than a direct substitute for growth-inhibiting antibiotics. Its potential depends on the pathogen, the virulence function being targeted, the condition of the host, and whether it is used alone or with conventional antimicrobial treatment.

Designing for Spectrum and Resistance

The emerging examples produce markedly different activity profiles despite targeting processes that are essential to the organisms they affect. Darobactin showed activity against a group of Gram-negative pathogens. Zosurabalpin displayed much more concentrated activity against A. baumannii. PC190723 showed selective antistaphylococcal activity.

These differences reinforce the need to define the intended spectrum during target and compound selection. The target must be present in a relevant form, and the compound must reach and engage it in each organism the therapy is expected to cover. Broad and pathogen-focused approaches should therefore be judged against a defined therapeutic purpose rather than ranked in the abstract.

Resistance must enter the same early evaluation. The case studies provide different experimental signals. Darobactin-resistant mutants mapped to BamA. Zosurabalpin resistance involved genes associated with its transporter target, LPS biosynthesis, and regulation. No teixobactin-resistant mutants were recovered in the experiments reported by Ling and colleagues.

Those findings are not directly comparable predictions of clinical durability. The studies examined different compounds, organisms, and experimental conditions. They do identify the questions that should accompany target selection: whether bacteria can change the target, bypass the inhibited process, alter related cellular functions, or reduce effective drug exposure. They also indicate where combination strategies may warrant investigation.

A full account of resistance requires examining what bacteria do after treatment applies selective pressure. At the target-selection stage, the immediate task is to identify plausible routes of escape early enough to influence compound design, spectrum, and combination planning.

A More Demanding Map of Antimicrobial Opportunity

The conventional mechanistic categories remain productive, but they represent only the first layer of the antimicrobial landscape. Opportunities persist within cell-wall biology, protein synthesis, nucleic-acid processes, metabolism, and membranes. Additional possibilities emerge through envelope assembly, molecular transport, conserved non-protein precursors, bacterial division, and virulence functions.

The strongest target-compound combinations will satisfy several requirements at once. The target must matter in the relevant organisms and conditions, while the intervention must reach it, discriminate adequately between pathogen and host, and produce the intended spectrum. Resistance liabilities must be understood, and target engagement must translate into whole-cell activity, acceptable tolerability, and useful performance in vivo.

A more demanding target map reduces a long list of possible bacterial vulnerabilities to the smaller set capable of supporting credible therapies. The mechanistic options extend beyond the target classes that dominate existing antibiotics. The harder task is determining which can withstand the biological, chemical, pharmacologic, and evolutionary tests that begin once a target is found.

References

  1. 1. Rousset, François, et al. “The impact of genetic diversity on gene essentiality within the Escherichia coli species.” Nature Microbiology. 6: 301–312 (2021). https://www.nature.com/articles/s41564-020-00839-y
  2. 2. Rosconi, Federico, et al. “A bacterial pan-genome makes gene essentiality strain-dependent and evolvable.” Nature Microbiology. 7: 1580–1592 (2022). https://www.nature.com/articles/s41564-022-01208-7
  3. 3. Silver, Lynn L. “Challenges of Antibacterial Discovery.” Clinical Microbiology Reviews. 24: 71–109 (2011). https://doi.org/10.1128/CMR.00030-10
  4. 4. Richter, Michelle F, et al. “Predictive compound accumulation rules yield a broad-spectrum antibiotic.” Nature. 545: 299–304 (2017). https://doi.org/10.1038/nature22308
  5. 5. Kapoor, Garima, Saurabh Saigal, and Ashok Elongavan. “Action and resistance mechanisms of antibiotics: A guide for clinicians.” Journal of Anaesthesiology Clinical Pharmacology. 33: 300–305 (2017). https://doi.org/10.4103/joacp.JOACP_349_15
  6. 6. Ling, Losee L, et al. “A new antibiotic kills pathogens without detectable resistance.” Nature. 517: 455–459 (2015). https://www.nature.com/articles/nature14098
  7. 7. Imai, Yu, et al. “A new antibiotic selectively kills Gram-negative pathogens.” Nature. 576: 459–464 (2019). https://www.nature.com/articles/s41586-019-1791-1
  8. 8. Zampaloni, Claudia, et al. “A novel antibiotic class targeting the lipopolysaccharide transporter.” Nature. 625: 566–571 (2024). https://www.nature.com/articles/s41586-023-06873-0
  9. 9. Haydon, David J, et al. “An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.” Science. 321: 1673–1675 (2008). https://pubmed.ncbi.nlm.nih.gov/18801997/
  10. 10. Dehbanipour, Razieh, and Zohreh Ghalavand. “Anti-virulence therapeutic strategies against bacterial infections: recent advances.” GERMS. 12: 262–275 (2022). https://doi.org/10.18683/germs.2022.1328

Stay Updated

Stay connected to keep up with the latest on antimicrobial resistance.

Name(Required)